Laxaro Your source for the latest research news
 aggressive care at end of life for advanced lung cancer patients linked to poorer outcomes
aggressive care at end of life for advanced lung cancer patients linked to poore

IMAGE: Mary Ersek, Ph.D., RN, FPCN, holds a joint appointment at the Department of Veterans Affairs and Penn Nursing.
view more Credit: Penn NursingPHILADELPHIA (May 25, 2017) - For patients with advanced cancer, aggressive care -- chemotherapy, mechanical ventilation, acute hospitalizations and intensive care unit admissions -- at the end of life is commonplace. Yet until now, little is known about the relationship between patients' and families' satisfaction with this aggressive care within the last 30 days of life.A new study, from the Department of Veterans Affairs and University of Pennsylvania School of Nursing (Penn Nursing), suggests that such care is not likely to contribute positively to patients' and families' experiences in the final days of life. Furthermore, the study resul

lung cancer may go undetected in kidney cancer patients

IMAGE: (L to R): Dr. James Brugarolas, Dr. Isaac Bowman, Dr. Ivan Pedrosa, and Dr. Payal Kapur studied lung cancer tumors in kidney cancer patients.
view more Credit: UT SouthwesternDALLAS - March 7, 2017 - Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C. Simmons Comprehensive Cancer Center's Kidney Cancer Program studied patients with metastatic kidney cancer to the lungs and found that 3.5 percent of the group had a primary lung cancer tumor that had gone undiagnosed. This distinction can affect treatment choices and rates of survival."Kidney cancer spreads primarily to the lungs making the detection of a primary lung cancer difficult. Lung cancer is typically more aggressive than kidney cancer. Undetected, lung cancer may spread and eventually kill

study finds not all women get appropriate care for cervical cancer

IMAGE: This is Shitanshu Uppal, MBBS.
view more Credit: Michigan MedicineANN ARBOR, Michigan -- Women with locally advanced cervical cancer whose treatment follows national guidelines for care have better survival, regardless of race, ethnicity or stage of cancer. But fewer than three out of five women received guideline-based care. For black and Hispanic women, it's just over half, a new study finds. And that could help explain why cervical cancer outcomes tend to be worse for these women.Researchers looked at records from 16,195 patients treated between 2004 and 2012 for locally advanced cervical cancer. Patient information was reported to the National Cancer Database, which represents 96 percent of the cervical cancer cases in the United States.To determine whether patients received c

prevention and prediction: understanding how lung cancer progresses

PHILADELPHIA - Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. A separate study revealed that the most commonly-targeted mutation of Non-Small Cell Lung Cancer (NSCLC) is most likely to result in progression at the primary site. Both projects will be presented this weekend at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco.
The first study (Oral Abstract Session, Presentation #11) deals with SCLC, which is a type of lung cancer with the strongest ties to smoking. It's particularly aggressive, with between 60 and

heart failure is as 'malignant' as some common cancers

A new analysis finds that, despite advances in care, men and women with a diagnosis of heart failure continue to have worse survival rates than patients with certain common cancers.The study included 56,658 adults in Scotland who were receiving care in a primary care setting, with a total of 147,938 person-years of follow-up. In men, heart failure was linked with worse survival than prostate cancer and bladder cancer, but better survival than lung cancer and colorectal cancer. In women, heart failure was linked with worse survival than breast cancer and colorectal cancer, but better survival than lung cancer and ovarian cancer."Our study shows that despite advances in the treatment of heart failure with newer drugs and devices, mortality rates for patients with heart failure remain signifi

advanced form of proton therapy shows promise for treating lung cancer recurrenc

An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center. Researchers found that after reirradiation with IMPT, the majority of patients were free from local recurrence one year following treatment and few experienced severe side effects.The data, presented at the 2017 Multidisciplinary Thoracic Cancers Symposium, is the first to analyze reirradiation of thoracic cancers with IMPT and offers hope for a patient population with few curative treatment options.Lung cancer is the leading cause of cancer death in the U.S. According to the American Cancer Society, more than 222,500 people will be diagnos

advanced prostate cancer treatment failure due to cell reprogramming

IMAGE: In mice with an aggressive form of prostate cancer, treatment with abiraterone -- a commonly used drug for advanced prostate cancer -- increased the size of the tumors compared to no treatment.
view more Credit: Cory Abate-Shen and Michael Shen / Columbia University Medical CenterNew York, NY (May 4, 2017)--Columbia University Medical Center (CUMC) researchers have discovered a molecular mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy. The findings, based on a study in mice, could help to determine which patients should avoid anti-androgen therapy and identify new treatments for people with advanced prostate cancer. The study was published online April14th in the journal Cancer Discovery.Since androg

fdg pet/ct found useful in certain lung cancer patients

Leesburg, VA, March 1, 2017-- FDG PET/CT is a valuable imaging tool for treatment assessment of patients with lung cancer, though systematic evidence for its comparative effectiveness with conventional imaging, such as chest CT, is still evolving. Authors of the study titled "The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer" published their findings in the February 2017 issue of the American Journal of Roentgenology. The study is available on the ARRS website accessible here. In this review, the authors summarized the existing evidence in the literature concerning use of PET/CT for both assessing the efficacy of treatment response and performing posttreatment follow-up of lung cancer."FDG PET/CT is most useful when there is clinical suspi

the iaslc atlas of pd-l1 immunohistochemistry (ihc) testing in lung cancer relea

Media Contact: Becky Bunn, MSc
Public Relations Manager
[email protected] | 720-325-2946 The IASLC Atlas of PD-L1 Immunohistochemistry (IHC) Testing in Lung Cancer Released
Publication the First to Collectively Discuss All Five PD-L1 IHC AssaysDENVER - Despite very encouraging progress in the development and use of immunotherapy for patients with non-small cell lung cancer, much confusion remains regarding patient selection for each therapy. There is no clear understanding among physicians, health care personnel or patients regarding which assay to use for programmed cell death ligand-1 (PD-L1) testing or whether the various assays are interchangeable because each assay was co-developed with a therapy. No publication to date has collectively evaluated all five of the currently avail

to screen or not to screen for lung cancer?

GLENVIEW, IL, March 13, 2017 - Lung cancer screening using a low-dose CT scan can be a lifesaving test for high-risk patients. While it offers clear benefits, incidental findings and radiation exposure mean there are some potential risks associated with yearly screening. Most patients do not fully understand the benefits or potential harms of a screening program, nor are they clear on exactly who should undergo testing. A new study in CHEST determined that a structured prescreening counseling and shared decision-making visit with health care professionals leads to a better understanding of the benefits and risks, as well as the eligibility criteria. Lung cancer screening is recommended for anyone over the age of 55 who has smoked for more than the equivalent of 30 pack-years. Pack-years ar

advanced prostate cancer treatment failure due to cell reprogramming

New York, NY (May 4, 2017)--Columbia University Medical Center (CUMC) researchers have discovered a molecular mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy. The findings, based on a study in mice, could help to determine which patients should avoid anti-androgen therapy and identify new treatments for people with advanced prostate cancer. The study was published online April14th in the journal Cancer Discovery.Since androgens (male hormones) are known to drive prostate cancer, patients with recurrent or advanced disease are typically treated with anti-androgen medications. However, most patients fail treatment and develop an aggressive form of prostate cancer known as castration-resistant prostate cancer, o

precision medicine improves treatment outcomes for some pancreatic cancer patien

University of Pittsburgh and UPMC researchers are paving the way for genome-targeted treatments in pancreatic cancer, an especially deadly form of cancer with few existing therapeutic options, according to a pair of recent studies. The first study used genomic profiling to identify targeted therapies that resulted in benefits for patients with pancreatic cancer, including one whose tumor contained a mutation in the anaplastic lymphoma kinase (ALK) gene. In the second study, researchers used existing drugs already treating other types of ALK-mutated cancers to improve outcomes in pancreatic cancer patients with the same genetic alterations."Together, these two findings begin to capture the promise of precision medicine in pancreatic cancer, which has so far not experienced the same success

why fewer blood cancer patients receive hospice care

Research has shown that patients with blood cancers are less likely to enroll in hospice care than patients with solid cancers, and the findings from a national survey suggest that concerns about the adequacy of hospice may prevent blood cancer specialists from referring their patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings point to potential means of improving end-of-life care for patients with blood cancers such as leukemia and lymphoma.Not only are these patients less likely to receive hospice care, but when they do enroll in hospice, they are also likely to spend less time under hospice care compared with other patients. Little is known about factors that account for these findings. Because blood cancer patients' decision

drug combination shows benefit in ras-driven cancers

BOSTON -- Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully. But in a presentation at the American Association for Cancer Research Annual Meeting on Monday, April 3, 2017 at 10:30 a.m., in Washington DC, Dana-Farber Cancer Institute scientists said a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene."Between one-quarter and one-third of patients got long-term clinical benefit," said Geoffrey Shapiro, MD, PhD, director of Dana-Farber's Early Drug Development Center. "Several patients were on the drugs for more than a year

scientists discover mechanism that causes cancer cells to self-destruct

Many cancer patients struggle with the adverse effects of chemotherapy, still the most prescribed cancer treatment. For patients with pancreatic cancer and other aggressive cancers, the forecast is more grim: there is no known effective therapy.A new Tel Aviv University study published last month in Oncotarget discloses the role of three proteins in killing fast-duplicating cancer cells while they're dividing. The research, led by Prof. Malka Cohen-Armon of TAU's Sackler School of Medicine, finds that these proteins can be specifically modified during the division process -- mitosis -- to unleash an inherent "death mechanism" that self-eradicates duplicating cancer cells."The discovery of an exclusive mechanism that kills cancer cells without impairing healthy cells, and the fact that this

rise in lung adenocarcinoma linked to 'light' cigarette use

COLUMBUS, Ohio -- A new study shows that so-called "light" cigarettes have no health benefits to smokers and have likely contributed to the rise of a certain form of lung cancer that occurs deep in the lungs. For this new study, researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and five other universities/cancer centers examined why the most common type of lung cancer, called adenocarcinoma, has increased over the last 50 years, rather than decreasing as smokers have been able to quit. Other types of lung cancer have been decreasing in relationship to fewer people smoking, but not lung adenocarcinoma. Because of this, lung adenocarcinoma is now the most common type of lung cancer.

serial analysis of ctcs may provide biomarker predictive of nsclc response to cr

Bottom Line: Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.Journal in Which the Study was Published: Cancer Research, a journal of the American Association for Cancer Research.Author: Françoise Farace, PhD, leader of the circulating cells team at Gustave Roussy, INSERM, Université Paris-Saclay, Villejuif, France.Background: About 4 percent of NSCLCs are driven by genetic aberrations called ALK gene rearrangements, according to Farace."The approval of the ALK-targeted therapeutic crizotinib has improved outco

the sun has got his hat on – have you? skin cancer on rise in the netherlands

Photo: Arena73 via Wikimedia CommonsThe sun has got his hat on, but have you? The number of people with aggressive skin cancer has continued to rise, reports the Netherlands Comprehensive Cancer Organisation IKNL on Friday.On Saturday, it will hold the fifth national skin cancer day to offer free checks and bring together patient associations, doctors and other experts.The organisation reports that in the last 15 years, the numbers of Dutch people with melanoma, an aggressive skin cancer, has risen dramatically from 1554 in 1990 to 5887 in 2015.One in five Dutch people is expected to get some form of skin cancer, making it one of the most common forms of cancer in the Netherlands. Most diagnosed cases are curable, and in 2014 there were 53,000 skin cancer patients recently registered – as

presstv-wearable device increases life of cancer patients

American scientists have introduced a wearable device that makes electric fields capable of increasing the lifespan of people diagnosed with aggressive brain cancer.The device is called the Optune therapy cap. It contains strips of electrodes connected by wires to a small generator kept in a bag. They create low intensity electric fields that disrupt cell reproduction.This helps make the cells die. Patients have to keep their heads shaved to wear the cap for 18 hours a day. Researchers say their studies show the new therapy can extend patients' lives, although it is no cure.Medics say the new method, in combination with chemotherapy, can increase the survival rate of brain cancer patients. Pilot tests are also underway for other cancers, such as pancreatic tumors.

nsw double murderer bruce burrell died of lung cancer, coroner finds

A notorious double murderer, who never revealed the whereabouts of his Sydney victims' bodies, died from lung cancer, a coroner has found.Bruce Burrell, 63, was serving a life sentence for killing Sydney women Kerry Whelan and Dorothy Davis in the 1990s when he died in a secure unit of Sydney's Prince of Wales Hospital in August last year.
Murderer Bruce Burrell took his secrets to the grave. Photo: Nick MoirDeputy State Coroner Derek Lee on Tuesday found Burrell had died of a small cell metastatic lung carcinoma, with heart disease having contributed to the death.The inquest heard Burrell had been diagnosed with advanced liver cancer two months before he died of lung cancer.None of his family were in court but a next of kin had been contacted and raised no issues with Burrell's care in

palbociclib in advanced breast cancer: disadvantages predominate in certain pati

Palbociclib (trade name: Ibrance) has been approved since November 2016 for the treatment of women with advanced hormone receptor-positive breast cancer who are not eligible for chemotherapy, radiotherapy or further surgery. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether this drug offers advantages for patients over the appropriate comparator therapies. According to the findings, such an added benefit is not proven: The dossier contained no data or no suitable data on several groups of patients. Where data were available, i.e. in the first-line treatment after menopause, severe side effects were more frequent under palbociclib in combination with letrozole than under letrozole alone, which resulted in an indicatio

a tough talk: how to improve cost transparency in cancer care

IMAGE: This is Dr. Erin Aakhus.
view more Credit: Penn MedicinePHILADELPHIA - Being transparent about the cost of cancer treatments with patients has been increasingly recommended to help minimize financial harm and improve care, but what's preventing or derailing those conversations is less understood. New findings from Penn Medicine that identified several barriers and key facilitators may help providers foster more successful discussions with their patients.
The abstract (#6597) will be presented at the 2017 American Society of Clinical Oncology annual meeting on June 5.
Several themes emerged in an analysis of interviews conducted between 22 cancer patients and 19 providers at Penn's Abramson Cancer Center and three of its affiliated community practices over the period of a year.

minority colorectal cancer patients report higher burden of poor quality-of-life

IMAGE: This is Michelle Hildebrandt, Ph.D.
view more Credit: MD Anderson Cancer CenterHOUSTON - A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics and blacks had a higher burden of poor health-related quality-of-life (HR-QoL) than white patients and that poor HR-QoL resulted in shorter median survival. Yet Hispanics had an average survival time of 85.4 months as compared to blacks at 47.8 months and whites at 43.2 months.The study, led by Michelle Hildebrandt, Ph.D., assistant professor of Epidemiology at The University of Texas MD Anderson Cancer Center, followed up on a prior MD Anderson survey that observed lower HR-QoL scores among minorities compared to white colorectal patients. The research

shared doctor-patient orthopaedic treatment decisions improve outcomes, patient

Well-informed patients who decide with their orthopaedic surgeon what treatment is best for them have better outcomes and higher patient satisfaction rates, according to new study presented today at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).Shared decision making (SDM), a key component of patient-centered health care, is a process in which doctors and patients work together to make decisions and select tests, treatments and care plans based on clinical evidence (imaging and test results) that balances risks and expected outcomes with patient preferences and values.Researchers surveyed more than 550 patients with hip or knee osteoarthritis; a slipped or ruptured (herniated) disc in the lower back; or lumbar spinal stenosis, a narrowing of the space aroun

penn studies find promise for innovations in liquid biopsies

IMAGE: This is a cluster of three circulating tumor cells.
view more Credit: Penn MedicinePHILADELPHIA - From using fluid in the lungs to better understand the potential of immunotherapy treatments in lung cancer, to tracking circulating tumor cells in prostate cancer, to conducting RNA sequencing of cancer cell clusters from the blood of pancreatic cancer patients, to finding new ways to biopsy tissue from patients who may have esophageal cancer, a series of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate the promise of new diagnostic methods. Three of the studies focus on liquid biopsies, an innovation which uses blood tests instead of surgical procedures in hopes of detecting cancer. Each research team will present their findings during the 2

Search Tags
study expands what we know about natural low cost ways to remove pollutants from water major counter terror raids disrupt plot to bring down aircraft pm fcc investigator says pai didn t give sinclair preferential treatment markets live asx set for sixth straight fall why china is serious about becoming the global leader on climate change macquarie group agrees to buy cargill petroleum business netflix wins an oscar for documentary short the white helmets file behind selling albums luke hodge suspended for round one by hawthorn leadership group lasers flesh out dino bird profile labour further from power than any time in my life says david miliband oxford mail irish national marriage melbourne how do you feel probably not as well as older swedish men hong kong s first female leader a tilted bridge over troubled waters mexico promised heat wave continues chandrapur balangir sizzle at 442 deg c macos mojave includes two desert themed wallpapers download here gujarat election 2017 india today axis exit poll predicts bjp majority game of thrones season 7 trailer the great war is here fastco explains why jony ive ordered this office chair for every workstation at apple park eolo ko nessuna connessione internet servizio in ripristino death toll in st petersburg terror attack rises to pesticide residue cyclone shelter activity grows cross checking system of bank accounts and incomes is good to go business rajputana rifles could coal ash be a viable source of rare earth metals chris christie s beach trip becomes twitter meme target presstv donald trump’s trade war coming into reality pier carlo padoan wa meth helpline calls left unanswered as funding cut plans for summit academy s superior expansion stalled over partner s mayoral bid school says look at these tiny great british bake off creations chicago tries to learn from new york crime fighting success amazon fresh which five energy cotton seeds
Facebook Twitter Google Plus Digg Share This

All rights reserved. © Laxaro 2016-2017 Run in 0.069 seconds